Cargando…

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

BACKGROUND: DepoVax(TM) is a novel non-emulsion depot-forming vaccine platform with the capacity to significantly enhance the immunogenicity of peptide cancer antigens. Naturally processed HLA-A2 restricted peptides presented by breast, ovarian and prostate cancer cells were used as antigens to crea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berinstein, Neil L, Karkada, Mohan, Morse, Michael A, Nemunaitis, John J, Chatta, Gurkamal, Kaufman, Howard, Odunsi, Kunle, Nigam, Rita, Sammatur, Leeladhar, MacDonald, Lisa D, Weir, Genevieve M, Stanford, Marianne M, Mansour, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479010/ https://www.ncbi.nlm.nih.gov/pubmed/22862954 http://dx.doi.org/10.1186/1479-5876-10-156

Ejemplares similares

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
por: Berinstein, Neil L, et al.
Publicado: (2015)

Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and anti-PD1 monoclonal antibody provides effective control of tumors in multiple models
por: Weir, Genevieve, et al.
Publicado: (2014)

Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillusanthracis spore inhalation challenge
por: Weir, Genevieve M., et al.
Publicado: (2019)

Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response
por: Weir, Genevieve M, et al.
Publicado: (2014)

Therapeutic vaccines and cancer: focus on DPX-0907
por: Karkada, Mohan, et al.
Publicado: (2014)

Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control
por: Brewer, Kimberly D., et al.
Publicado: (2018)

Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo
por: Weir, Genevieve M., et al.
Publicado: (2017)

Plasma biomarker analysis of ovarian cancer patients undergoing immunotherapy with therapeutic cancer vaccine DPX-Survivac
por: Karkada, Mohan, et al.
Publicado: (2015)

Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide
por: Weir, Genevieve M., et al.
Publicado: (2016)

Immunological and polyfunctional T cell profiling following therapy with DPX-Survivac as a predictive tool of vaccine efficacy
por: Karkada, Mohan, et al.
Publicado: (2013)

Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer
por: Eng, Kevin H., et al.
Publicado: (2015)

Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness
por: Liu, Xiaozhuo, et al.
Publicado: (2022)

T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
por: Yamauchi, Takayoshi, et al.
Publicado: (2021)

Role of tumor microenvironment in the efficacy of BCG therapy
por: Ibrahim, Omar M, et al.
Publicado: (2020)

NFκB-Activated COX2/PGE(2)/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues
por: Ibrahim, Omar M., et al.
Publicado: (2021)

Loss of MAGEC3 Expression Is Associated with Prognosis in Advanced Ovarian Cancers
por: Ellegate, James, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers
por: Soni, Amy, et al.
Publicado: (2015)

Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration
por: Karkada, Mohan, et al.
Publicado: (2013)

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
por: Dolan, Melissa, et al.
Publicado: (2019)

Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer
por: Matsuzaki, Junko, et al.
Publicado: (2022)

A randomized phase II study of pazopanib in hormone sensitive prostate cancer: a University of Chicago Phase II Consortium/ Department of Defense Prostate Cancer Clinical Trials Consortium study
por: Ward, James E., et al.
Publicado: (2011)

Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines
por: DeBay, Drew R, et al.
Publicado: (2015)

A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study
por: Langley, Joanne M, et al.
Publicado: (2018)

Novel genetic variants in miR-191 gene and familial ovarian cancer
por: Shen, Jie, et al.
Publicado: (2010)

Oncologist uptake of comprehensive genomic profile guided targeted therapy
por: Nesline, Mary K., et al.
Publicado: (2019)

Transmission of X-linked Ovarian Cancer: Characterization and Implications
por: Etter, John Lewis, et al.
Publicado: (2020)

Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
por: Weir, Genevieve M., et al.
Publicado: (2011)

Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform
por: MacDonald, Lisa D., et al.
Publicado: (2017)

Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)
por: Arnold, Susanne M., et al.
Publicado: (2017)

Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model
por: Dirk, Brennan S., et al.
Publicado: (2021)

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
por: Huang, Ruea-Yea, et al.
Publicado: (2016)

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing
por: Dy, Grace K., et al.
Publicado: (2019)

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8(+) T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
por: Huang, Ruea-Yea, et al.
Publicado: (2015)

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers
por: Seagle, Brandon-Luke L., et al.
Publicado: (2015)

Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer
por: Ramakrishnan, Swathi, et al.
Publicado: (2019)

Sublethal Radiation Affects Antigen Processing and Presentation Genes to Enhance Immunogenicity of Cancer Cells
por: Punnanitinont, Achamaporn, et al.
Publicado: (2020)

A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation
por: KIM, KANG-MI, et al.
Publicado: (2012)

Ex-Th17 Foxp3+ T cells - a novel subset of Foxp3+ T cells induced in cancer
por: Downs-Canner, Stephanie, et al.
Publicado: (2015)

Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy
por: Mikucki, Maryann E., et al.
Publicado: (2016)

Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression
por: Agnani, Deep, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_82ht94hm8s2ruroblbtqvo9o3s